The PACIFIC trial marked a new era in the treatment of stage III unresectable NSCLC, establishing durvalumab consolidation as new standard of care worldwide, with about 14 % increase of long-term survival and half of the patients alive at 4 years. A series of intensified immune-checkpoint inhibition regimens are currently under investigation in clinical trials in order to optimize the therapeutic benefit obtained in this population, while the identification of personalized approaches as well as the development of effective treatments in the post-durvalumab progression setting represent an actual and controversial topic for clinical lung cancer research. This review describes the current real-word treatment scenario for stage III unresectable NSCLC in Italy, and provides an updated overview of the upcoming therapeutic strategies under clinical investigation, discussing the most relevant challenges and opportunities featuring the post-PACIFIC era.

Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era

Passiglia F.;Leone G.;Delcuratolo M. D.;Reale M. L.;Bertaglia V.;Consito L.;Bironzo P.;Capelletto E.;Novello S.
2021

Abstract

The PACIFIC trial marked a new era in the treatment of stage III unresectable NSCLC, establishing durvalumab consolidation as new standard of care worldwide, with about 14 % increase of long-term survival and half of the patients alive at 4 years. A series of intensified immune-checkpoint inhibition regimens are currently under investigation in clinical trials in order to optimize the therapeutic benefit obtained in this population, while the identification of personalized approaches as well as the development of effective treatments in the post-durvalumab progression setting represent an actual and controversial topic for clinical lung cancer research. This review describes the current real-word treatment scenario for stage III unresectable NSCLC in Italy, and provides an updated overview of the upcoming therapeutic strategies under clinical investigation, discussing the most relevant challenges and opportunities featuring the post-PACIFIC era.
157
85
91
Consolidation; Immune-checkpoint inhibitors; Non-small cell lung cancer; PD-1/PD-L1; Stage III
Passiglia F.; Leone G.; Olmetto E.; Delcuratolo M.D.; Tabbo F.; Reale M.L.; Bertaglia V.; Consito L.; Bironzo P.; Capelletto E.; Novello S.
File in questo prodotto:
File Dimensione Formato  
Immune-checkpoint inhibition in stage III unresectable NSCLC_ Challenges and opportunities in the post-PACIFIC era _ Elsevier Enhanced Reader.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 3.63 MB
Formato Adobe PDF
3.63 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1790645
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact